Genotypic Variation in thepolGene of HIV Type 1 in an Antiretroviral Treatment-Naive Population in Rural Southwestern Uganda
- 1 October 2006
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 22 (10), 985-992
- https://doi.org/10.1089/aid.2006.22.985
Abstract
The majority of studies of HIV-1 drug resistance have involved subtype B viruses. Here we have characterized subtype distribution and determined the levels of polymorphism at protease (PR) and reverse transcriptase (RT) drug resistance positions, in antiretroviral treatment-naive HIV-positive Ugandan patients. We have also investigated codon usage variability at these positions and assessed intersubtype recombination within the pol gene. The study population consisted of 187 patients, from a cohort established by the UK Medical Research Council Programme on AIDS in Uganda in 1990. Results indicate that 28.3% of patients were infected with subtype A (n = 53), 64.2% subtype D (n = 120), 6.4% A/D recombinant (n = 12), and 1.1% subtype C (n = 2). Variation in amino acid usage at drug resistance-associated positions was minimal between the two main subtypes (A and D) in RT, but there was appreciable variation in PR. Codon usage, however, was considerably more variable between subtypes A and D in both PR and RT. Thus, while no natural high-level resistance to antiretroviral therapy was detected in this cohort, subtypes A and D may possess different genetic barriers to be overcome in order to achieve resistance. With the increasing introduction of antiretroviral therapy into Africa, such information will be vital in our understanding and evaluation of the development of drug resistance as it occurs, and how to interpret resistance data the type of which has rarely previously been seen. This analysis also significantly increases the number of Ugandan PR and RT sequences characterized to date.Keywords
This publication has 38 references indexed in Scilit:
- A statistical model for HIV-1 sequence classification using the subtype analyser (STAR)Bioinformatics, 2005
- Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global CollaborationPLoS Medicine, 2005
- The Relationship between HIV Type 1 Disease Progression and V3 Serotype in a Rural Ugandan CohortAIDS Research and Human Retroviruses, 2004
- Drug Resistance Testing Provides Evidence of the Globalization of HIV Type 1: A New Circulating Recombinant FormAIDS Research and Human Retroviruses, 2004
- Development of a Novel Human Immunodeficiency Virus Type 1 Subtyping Tool, Subtype Analyzer (STAR): Analysis of Subtype Distribution in LondonAIDS Research and Human Retroviruses, 2004
- Identification of Ugandan HIV Type 1 Variants with Unique Patterns of Recombination in pol Involving Subtypes A and DAIDS Research and Human Retroviruses, 2002
- Human Immunodeficiency Virus Type 1 Reverse‐Transcriptase and Protease Subtypes: Classification, Amino Acid Mutation Patterns, and Prevalence in a Northern California Clinic‐Based PopulationThe Journal of Infectious Diseases, 2001
- Resistance to Antiretroviral Therapy Among Patients in UgandaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Molecular Epidemiology of HIV Type 1 in a Rural Community in Southwest UgandaAIDS Research and Human Retroviruses, 2000
- HIV-1 RNA Levels in an African Population-Based Cohort and Their Relation to CD4 Lymphocyte Counts and World Health Organization Clinical StagingJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999